Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ROR1/CD3 T-cell-engager NVG-111

A bispecific antibody and T-cell engager directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-ROR1/CD3 T-cell engager NVG-111 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and ROR1 found on ROR1-expressing tumor cells. This activates and redirects CTLs to ROR1-expressing tumor cells, which results in the CTL-mediated death of ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in many types of hematological malignancies. It plays key roles in tumor cell proliferation and survival.
Synonym:anti-ROR1/CD3 bispecific antibody NVG-111
Code name:NVG 111
NVG-111
NVG111
Search NCI's Drug Dictionary